Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + propranolol
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + propranolol is a combination therapy being investigated for the treatment of unresectable stage III or IV melanoma. Pembrolizumab is a humanized monoclonal antibody that acts as a checkpoint inhibitor by binding to the programmed cell death-1 (PD-1) receptor, thereby preventing its interaction with PD-L1 and PD-L2 and enhancing T-cell mediated anti-tumor activity. Propranolol is a non-selective beta-adrenergic receptor antagonist. The combination, pioneered in clinical trials by Roswell Park Comprehensive Cancer Center, aims to counteract the immunosuppressive effects of stress-induced beta-adrenergic signaling within the tumor microenvironment. Research suggests that blocking the beta-adrenergic pathway can improve the efficacy of PD-1 inhibitors by reducing the immunosuppressive nature of the tumor site, potentially increasing the objective response rate in treatment-naive patients.
- Brand names
- KeytrudaInderalInnoPran XLHemangeol
- Other names
- pembrolizumabpropranolol hydrochloridepropranolol
02
Targets
ADRB2 (β2)ADRB1 (β1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + propranolol.